{
    "guideline_identifier": "PIIS0923753424007294.txt",
    "cancer_focus": {
        "primary_cancer": [
            "Diffuse Large B-Cell Lymphoma (DLBCL)",
            "Burkitt Lymphoma (BL)",
            "Plasmablastic Lymphoma (PBL)",
            "Primary Effusion Lymphoma (PEL)",
            "Primary Central Nervous System Lymphoma (PCNSL)",
            "Hodgkin Lymphoma (HL)"
        ],
        "related_syndrome_or_condition": [
            "HIV-Associated Lymphomas",
            "HHV-8-associated Multicentric Castleman Disease (MCD)",
            "Epstein-Barr Virus (EBV) co-infection"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Ann Arbor staging, contrast-enhanced CT, FDG-PET/CT",
            "risk_group": "CD4 ≥50 cells/µL",
            "treatment_plans": [
                {
                    "clinical_context": "DLBCL first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "R-CHOP ×6 cycles (3-week intervals) or DA-R-EPOCH ×6 cycles. CNS prophylaxis: Intrathecal MTX ± cytarabine or IV MTX",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD20",
                            "status": "Positive",
                            "testing_guidance": "IHC"
                        },
                        {
                            "name": "CD4",
                            "status": "≥50 cells/µL",
                            "testing_guidance": "Flow cytometry"
                        }
                    ],
                    "esmo_evidence_level": "II A, III C"
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor staging, contrast-enhanced CT, FDG-PET/CT",
            "risk_group": "CD4 <50 cells/µL",
            "treatment_plans": [
                {
                    "clinical_context": "DLBCL first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Avoid rituximab; use chemotherapy (e.g., CHOP) ×6 cycles. CNS prophylaxis: Intrathecal MTX ± cytarabine or IV MTX",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD4",
                            "status": "<50 cells/µL",
                            "testing_guidance": "Flow cytometry"
                        }
                    ],
                    "esmo_evidence_level": "III C"
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor staging, tumor lysis syndrome assessment",
            "risk_group": "High-risk/CNS involvement",
            "treatment_plans": [
                {
                    "clinical_context": "Burkitt Lymphoma (BL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "R-CODOX-M/R-IVAC. CNS prophylaxis: Weekly intrathecal MTX until CSF clearance",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor staging, tumor lysis syndrome assessment",
            "risk_group": "Low-risk",
            "treatment_plans": [
                {
                    "clinical_context": "Burkitt Lymphoma (BL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "DA-R-EPOCH ×6 cycles",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor staging",
            "risk_group": "Localized disease",
            "treatment_plans": [
                {
                    "clinical_context": "Plasmablastic Lymphoma (PBL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "CHOP/EPOCH + radiotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor staging",
            "risk_group": "Advanced disease",
            "treatment_plans": [
                {
                    "clinical_context": "Plasmablastic Lymphoma (PBL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Polychemotherapy ± bortezomib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor staging",
            "risk_group": "CD20+",
            "treatment_plans": [
                {
                    "clinical_context": "Primary Effusion Lymphoma (PEL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "CHOP or DA-EPOCH ± rituximab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD20",
                            "status": "Positive",
                            "testing_guidance": "IHC"
                        }
                    ],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "MRI (gold standard), CSF analysis",
            "risk_group": "All cases",
            "treatment_plans": [
                {
                    "clinical_context": "Primary CNS Lymphoma (PCNSL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Rituximab + HD-MTX (3 g/m²) + ART",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III A"
                },
                {
                    "clinical_context": "PCNSL consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "MATRix regimen (rituximab/MTX/cytarabine/thiotepa) → ASCT if HIV-controlled",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [
                        {
                            "name": "CD4",
                            "status": "Adequate count",
                            "testing_guidance": "Flow cytometry"
                        },
                        {
                            "name": "Viral Load",
                            "status": "Suppressed",
                            "testing_guidance": "PCR"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor System (Stage II-IV)",
            "risk_group": "Limited stage",
            "treatment_plans": [
                {
                    "clinical_context": "Hodgkin Lymphoma (HL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ABVD ×2 cycles → 20 Gy involved-site RT",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Ann Arbor System (Stage II-IV)",
            "risk_group": "Advanced stage",
            "treatment_plans": [
                {
                    "clinical_context": "Hodgkin Lymphoma (HL) first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ABVD ×6 or BEACOPP₆₋₈ cycles → RT for PET-positive residual disease",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Hodgkin Lymphoma (HL) first-line alternative",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Brentuximab vedotin + AVD ×6 cycles (Phase 2 trial AMC 085)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "CD30",
                            "status": "Positive",
                            "testing_guidance": "IHC"
                        }
                    ],
                    "esmo_evidence_level": "II"
                }
            ]
        },
        {
            "staging_criteria": "Post-autologous stem cell transplant",
            "risk_group": "High-risk of relapse/progression",
            "treatment_plans": [
                {
                    "clinical_context": "Hodgkin Lymphoma (HL) consolidation",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Brentuximab vedotin (AETHERA Phase 3 trial)",
                    "treatment_line": "Consolidation",
                    "biomarker_requirements": [
                        {
                            "name": "CD30",
                            "status": "Positive",
                            "testing_guidance": "IHC"
                        }
                    ],
                    "esmo_evidence_level": "I"
                }
            ]
        },
        {
            "staging_criteria": "Diagnostic criteria (J Acquir Immune Defic Syndr 2014)",
            "risk_group": "HHV8/KSHV-positive",
            "treatment_plans": [
                {
                    "clinical_context": "HIV-associated MCD first-line",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Rituximab monotherapy ×4 cycles",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "HHV-8/KSHV",
                            "status": "Positive",
                            "testing_guidance": "LANA-IHC, PCR"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                },
                {
                    "clinical_context": "Severe HIV-associated MCD",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Rituximab + liposomal doxorubicin",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "HHV-8/KSHV",
                            "status": "Positive",
                            "testing_guidance": "LANA-IHC, PCR"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                }
            ]
        },
        {
            "staging_criteria": "Relapsed disease",
            "risk_group": "All cases",
            "treatment_plans": [
                {
                    "clinical_context": "DLBCL relapsed/refractory",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Salvage immunochemotherapy (R-DHAP, R-ICE) → ASCT if chemosensitive",
                    "treatment_line": "Relapsed/Refractory",
                    "biomarker_requirements": [
                        {
                            "name": "CD20",
                            "status": "Positive",
                            "testing_guidance": "IHC"
                        }
                    ],
                    "esmo_evidence_level": "III A"
                },
                {
                    "clinical_context": "DLBCL relapsed/refractory with controlled HIV",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "CAR-T therapy if CD19+",
                    "treatment_line": "Relapsed/Refractory",
                    "biomarker_requirements": [
                        {
                            "name": "CD19",
                            "status": "Positive",
                            "testing_guidance": "IHC or flow cytometry"
                        },
                        {
                            "name": "CD4",
                            "status": "≥200 cells/µL",
                            "testing_guidance": "Flow cytometry"
                        },
                        {
                            "name": "Viral Load",
                            "status": "Suppressed",
                            "testing_guidance": "PCR"
                        }
                    ],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Hodgkin Lymphoma relapsed/refractory",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab vs. brentuximab vedotin (KEYNOTE-204 Phase 3) or nivolumab",
                    "treatment_line": "Relapsed/Refractory",
                    "biomarker_requirements": [
                        {
                            "name": "CD30",
                            "status": "Positive",
                            "testing_guidance": "IHC"
                        }
                    ],
                    "esmo_evidence_level": "I"
                },
                {
                    "clinical_context": "MCD relapse management",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Rituximab rechallenge or CHOP",
                    "treatment_line": "Relapsed/Refractory",
                    "biomarker_requirements": [
                        {
                            "name": "HHV-8/KSHV",
                            "status": "Positive",
                            "testing_guidance": "LANA-IHC, PCR"
                        }
                    ],
                    "esmo_evidence_level": ""
                }
            ]
        }
    ],
    "biomarker_clinical_significance": [
        {
            "name": "CD20",
            "clinical_significance": "Determines rituximab eligibility; avoid if negative in PBL/PEL"
        },
        {
            "name": "EBV",
            "clinical_significance": "Indicates pathogenesis in PEL, PBL, PCNSL; prognostic in HL"
        },
        {
            "name": "HHV-8/KSHV",
            "clinical_significance": "Diagnostic for PEL and MCD; dictates therapy for MCD"
        },
        {
            "name": "MYC/BCL2/BCL6",
            "clinical_significance": "Excludes double/triple-hit lymphoma (DLBCL/BL)"
        },
        {
            "name": "CD4 Count",
            "clinical_significance": "Predicts treatment tolerance (e.g., rituximab if ≥50 cells/µL)"
        },
        {
            "name": "Viral Load",
            "clinical_significance": "Determines eligibility for advanced therapies (e.g., CAR-T)"
        },
        {
            "name": "CSF Involvement",
            "clinical_significance": "Guides CNS prophylaxis/treatment escalation"
        },
        {
            "name": "CD30",
            "clinical_significance": "Predicts efficacy of brentuximab vedotin in HL"
        }
    ]
}